RANIBIZUMAB

N/A

Manufactured by Genentech, Inc.

41,498 FDA adverse event reports analyzed

Last updated: 2026-04-14

About RANIBIZUMAB

RANIBIZUMAB is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Genentech, Inc.. The most commonly reported adverse reactions for RANIBIZUMAB include DEATH, VISUAL ACUITY REDUCED, OFF LABEL USE, VISUAL IMPAIRMENT, CEREBROVASCULAR ACCIDENT. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for RANIBIZUMAB.

Top Adverse Reactions

DEATH3,785 reports
VISUAL ACUITY REDUCED2,887 reports
OFF LABEL USE1,676 reports
VISUAL IMPAIRMENT1,623 reports
CEREBROVASCULAR ACCIDENT1,235 reports
DRUG INEFFECTIVE1,196 reports
EYE HAEMORRHAGE1,041 reports
NO ADVERSE EVENT1,038 reports
BLINDNESS1,036 reports
VISION BLURRED1,028 reports
EYE PAIN954 reports
RETINAL HAEMORRHAGE789 reports
ENDOPHTHALMITIS727 reports
MYOCARDIAL INFARCTION688 reports
CATARACT681 reports
VITREOUS FLOATERS618 reports
FALL589 reports
MALAISE582 reports
MACULAR OEDEMA573 reports
HEADACHE484 reports
BLINDNESS UNILATERAL463 reports
OCULAR HYPERAEMIA451 reports
VITREOUS HAEMORRHAGE447 reports
AGE RELATED MACULAR DEGENERATION444 reports
DISEASE PROGRESSION424 reports
EYE DISORDER419 reports
INTRAOCULAR PRESSURE INCREASED407 reports
RETINAL OEDEMA367 reports
MACULAR DEGENERATION358 reports
HYPERTENSION357 reports
CHOROIDAL NEOVASCULARISATION353 reports
RETINAL DETACHMENT352 reports
PAIN340 reports
PNEUMONIA338 reports
EYE IRRITATION332 reports
RETINAL PIGMENT EPITHELIAL TEAR320 reports
SUBRETINAL FLUID316 reports
DETACHMENT OF RETINAL PIGMENT EPITHELIUM308 reports
TRANSIENT ISCHAEMIC ATTACK304 reports
DIZZINESS302 reports
LACRIMATION INCREASED287 reports
NAUSEA277 reports
PRODUCT USE ISSUE277 reports
GLAUCOMA276 reports
COUGH271 reports
CEREBRAL INFARCTION270 reports
DYSPNOEA261 reports
HAEMORRHAGE257 reports
EYE INFLAMMATION247 reports
BLOOD PRESSURE INCREASED243 reports
CONDITION AGGRAVATED240 reports
INTENTIONAL PRODUCT USE ISSUE233 reports
DIABETIC RETINAL OEDEMA230 reports
EYE PRURITUS226 reports
FATIGUE219 reports
ATRIAL FIBRILLATION209 reports
DRY EYE206 reports
METAMORPHOPSIA202 reports
EYE INFECTION200 reports
RETINAL VEIN OCCLUSION199 reports
POLYPOIDAL CHOROIDAL VASCULOPATHY198 reports
NEOVASCULAR AGE RELATED MACULAR DEGENERATION197 reports
EYE SWELLING196 reports
EYE DISCHARGE188 reports
DISEASE RECURRENCE185 reports
INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION183 reports
PHOTOPSIA180 reports
UVEITIS180 reports
CYSTOID MACULAR OEDEMA172 reports
ASTHENIA170 reports
ARTHRALGIA164 reports
INJECTION SITE PAIN164 reports
URINARY TRACT INFECTION162 reports
CARDIAC DISORDER156 reports
DEAFNESS154 reports
RETINAL SCAR153 reports
RETINAL DISORDER149 reports
DIABETES MELLITUS144 reports
RETINAL EXUDATES143 reports
CARDIAC FAILURE141 reports
NASOPHARYNGITIS141 reports
OCULAR DISCOMFORT141 reports
CARDIAC FAILURE CONGESTIVE140 reports
HYPERSENSITIVITY137 reports
PHOTOPHOBIA137 reports
OCULAR HYPERTENSION136 reports
VITRITIS136 reports
BLINDNESS TRANSIENT135 reports
RENAL FAILURE135 reports
DRUG HYPERSENSITIVITY133 reports
RETINAL TEAR133 reports
CONFUSIONAL STATE132 reports
VITREOUS DETACHMENT132 reports
PRODUCT USE IN UNAPPROVED INDICATION131 reports
FOREIGN BODY SENSATION IN EYES130 reports
VOMITING130 reports
CHEST PAIN125 reports
HYPOACUSIS125 reports
GAIT DISTURBANCE124 reports
MACULOPATHY124 reports

Report Outcomes

Out of 26,169 classified reports for RANIBIZUMAB:

Serious 85.1%Non-Serious 14.9%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female12,770 (55.7%)
Male9,952 (43.4%)
Unknown210 (0.9%)

Reports by Age

Age 80474 reports
Age 82416 reports
Age 81414 reports
Age 72411 reports
Age 84403 reports
Age 79397 reports
Age 78389 reports
Age 85388 reports
Age 77381 reports
Age 86374 reports
Age 83372 reports
Age 74363 reports
Age 75358 reports
Age 76334 reports
Age 70332 reports
Age 73316 reports
Age 87309 reports
Age 71304 reports
Age 88296 reports
Age 89284 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with RANIBIZUMAB?

This profile reflects 41,498 FDA FAERS reports that mention RANIBIZUMAB. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for RANIBIZUMAB?

Frequently reported terms in FAERS include DEATH, VISUAL ACUITY REDUCED, OFF LABEL USE, VISUAL IMPAIRMENT, CEREBROVASCULAR ACCIDENT, DRUG INEFFECTIVE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures RANIBIZUMAB?

Labeling and FAERS entries often list Genentech, Inc. in connection with RANIBIZUMAB. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.